290 related articles for article (PubMed ID: 29654064)
1. Antibody-Dependent Cellular Phagocytosis by Macrophages is a Novel Mechanism of Action of Elotuzumab.
Kurdi AT; Glavey SV; Bezman NA; Jhatakia A; Guerriero JL; Manier S; Moschetta M; Mishima Y; Roccaro A; Detappe A; Liu CJ; Sacco A; Huynh D; Tai YT; Robbins MD; Azzi J; Ghobrial IM
Mol Cancer Ther; 2018 Jul; 17(7):1454-1463. PubMed ID: 29654064
[TBL] [Abstract][Full Text] [Related]
2. Mechanisms of NK Cell Activation and Clinical Activity of the Therapeutic SLAMF7 Antibody, Elotuzumab in Multiple Myeloma.
Campbell KS; Cohen AD; Pazina T
Front Immunol; 2018; 9():2551. PubMed ID: 30455698
[TBL] [Abstract][Full Text] [Related]
3. Elotuzumab enhances natural killer cell activation and myeloma cell killing through interleukin-2 and TNF-α pathways.
Balasa B; Yun R; Belmar NA; Fox M; Chao DT; Robbins MD; Starling GC; Rice AG
Cancer Immunol Immunother; 2015 Jan; 64(1):61-73. PubMed ID: 25287778
[TBL] [Abstract][Full Text] [Related]
4. Potent in vitro and in vivo activity of an Fc-engineered humanized anti-HM1.24 antibody against multiple myeloma via augmented effector function.
Tai YT; Horton HM; Kong SY; Pong E; Chen H; Cemerski S; Bernett MJ; Nguyen DH; Karki S; Chu SY; Lazar GA; Munshi NC; Desjarlais JR; Anderson KC; Muchhal US
Blood; 2012 Mar; 119(9):2074-82. PubMed ID: 22246035
[TBL] [Abstract][Full Text] [Related]
5. Enhanced SLAMF7 Homotypic Interactions by Elotuzumab Improves NK Cell Killing of Multiple Myeloma.
Pazina T; James AM; Colby KB; Yang Y; Gale A; Jhatakia A; Kearney AY; Graziano RF; Bezman NA; Robbins MD; Cohen AD; Campbell KS
Cancer Immunol Res; 2019 Oct; 7(10):1633-1646. PubMed ID: 31431433
[TBL] [Abstract][Full Text] [Related]
6. Combinatorial efficacy of anti-CS1 monoclonal antibody elotuzumab (HuLuc63) and bortezomib against multiple myeloma.
van Rhee F; Szmania SM; Dillon M; van Abbema AM; Li X; Stone MK; Garg TK; Shi J; Moreno-Bost AM; Yun R; Balasa B; Ganguly B; Chao D; Rice AG; Zhan F; Shaughnessy JD; Barlogie B; Yaccoby S; Afar DE
Mol Cancer Ther; 2009 Sep; 8(9):2616-24. PubMed ID: 19723891
[TBL] [Abstract][Full Text] [Related]
7. SAR650984, a novel humanized CD38-targeting antibody, demonstrates potent antitumor activity in models of multiple myeloma and other CD38+ hematologic malignancies.
Deckert J; Wetzel MC; Bartle LM; Skaletskaya A; Goldmacher VS; Vallée F; Zhou-Liu Q; Ferrari P; Pouzieux S; Lahoute C; Dumontet C; Plesa A; Chiron M; Lejeune P; Chittenden T; Park PU; Blanc V
Clin Cancer Res; 2014 Sep; 20(17):4574-83. PubMed ID: 24987056
[TBL] [Abstract][Full Text] [Related]
8. Elotuzumab directly enhances NK cell cytotoxicity against myeloma via CS1 ligation: evidence for augmented NK cell function complementing ADCC.
Collins SM; Bakan CE; Swartzel GD; Hofmeister CC; Efebera YA; Kwon H; Starling GC; Ciarlariello D; Bhaskar S; Briercheck EL; Hughes T; Yu J; Rice A; Benson DM
Cancer Immunol Immunother; 2013 Dec; 62(12):1841-9. PubMed ID: 24162108
[TBL] [Abstract][Full Text] [Related]
9. Antibody-mediated phagocytosis contributes to the anti-tumor activity of the therapeutic antibody daratumumab in lymphoma and multiple myeloma.
Overdijk MB; Verploegen S; Bögels M; van Egmond M; Lammerts van Bueren JJ; Mutis T; Groen RW; Breij E; Martens AC; Bleeker WK; Parren PW
MAbs; 2015; 7(2):311-21. PubMed ID: 25760767
[TBL] [Abstract][Full Text] [Related]
10. Elotuzumab for the treatment of multiple myeloma.
Wang Y; Sanchez L; Siegel DS; Wang ML
J Hematol Oncol; 2016 Jul; 9(1):55. PubMed ID: 27417553
[TBL] [Abstract][Full Text] [Related]
11. Cyclophosphamide alters the tumor cell secretome to potentiate the anti-myeloma activity of daratumumab through augmentation of macrophage-mediated antibody dependent cellular phagocytosis.
Naicker SD; Feerick CL; Lynch K; Swan D; McEllistrim C; Henderson R; Leonard NA; Treacy O; Natoni A; Rigalou A; Cabral J; Chiu C; Sasser K; Ritter T; O'Dwyer M; Ryan AE
Oncoimmunology; 2021 Jan; 10(1):1859263. PubMed ID: 33552684
[TBL] [Abstract][Full Text] [Related]
12. Monoclonal antibody Daratumumab promotes macrophage-mediated anti-myeloma phagocytic activity via engaging FC gamma receptor and activation of macrophages.
Gao Y; Li L; Zheng Y; Zhang W; Niu B; Li Y
Mol Cell Biochem; 2022 Aug; 477(8):2015-2024. PubMed ID: 35397683
[TBL] [Abstract][Full Text] [Related]
13. An Fc engineering approach that modulates antibody-dependent cytokine release without altering cell-killing functions.
Kinder M; Greenplate AR; Strohl WR; Jordan RE; Brezski RJ
MAbs; 2015; 7(3):494-504. PubMed ID: 25933349
[TBL] [Abstract][Full Text] [Related]
14. The Clinical Pharmacology of Elotuzumab.
Passey C; Sheng J; Mora J; Tendolkar A; Robbins M; Dodge R; Roy A; Bello A; Gupta M
Clin Pharmacokinet; 2018 Mar; 57(3):297-313. PubMed ID: 28779463
[TBL] [Abstract][Full Text] [Related]
15. PD-1 blockade enhances elotuzumab efficacy in mouse tumor models.
Bezman NA; Jhatakia A; Kearney AY; Brender T; Maurer M; Henning K; Jenkins MR; Rogers AJ; Neeson PJ; Korman AJ; Robbins MD; Graziano RF
Blood Adv; 2017 May; 1(12):753-765. PubMed ID: 29296719
[TBL] [Abstract][Full Text] [Related]
16. A review discussing elotuzumab and its use in the second-line plus treatment of multiple myeloma.
Offidani M; Corvatta L
Future Oncol; 2018 Feb; 14(4):319-329. PubMed ID: 29091475
[TBL] [Abstract][Full Text] [Related]
17. Monoclonal Antibodies in Multiple Myeloma: A New Wave of the Future.
Sherbenou DW; Mark TM; Forsberg P
Clin Lymphoma Myeloma Leuk; 2017 Sep; 17(9):545-554. PubMed ID: 28734795
[TBL] [Abstract][Full Text] [Related]
18. Human anti-CAIX antibodies mediate immune cell inhibition of renal cell carcinoma in vitro and in a humanized mouse model in vivo.
Chang DK; Moniz RJ; Xu Z; Sun J; Signoretti S; Zhu Q; Marasco WA
Mol Cancer; 2015 Jun; 14():119. PubMed ID: 26062742
[TBL] [Abstract][Full Text] [Related]
19. Simultaneous exposure to FcγR and FcαR on monocytes and macrophages enhances antitumor activity in vivo.
Li B; Xu L; Tao F; Xie K; Wu Z; Li Y; Li J; Chen K; Pi C; Mendelsohn A; Larrick JW; Gu H; Fang J
Oncotarget; 2017 Jun; 8(24):39356-39366. PubMed ID: 28454118
[TBL] [Abstract][Full Text] [Related]
20. Fratricide of NK Cells in Daratumumab Therapy for Multiple Myeloma Overcome by
Wang Y; Zhang Y; Hughes T; Zhang J; Caligiuri MA; Benson DM; Yu J
Clin Cancer Res; 2018 Aug; 24(16):4006-4017. PubMed ID: 29666301
[No Abstract] [Full Text] [Related]
[Next] [New Search]
